A new role for estrogen receptor a in cell proliferation and cancer: Activating the anticipatory unfolded protein response

Mara Livezey, Ji Eun Kim, David J. Shapiro

Research output: Contribution to journalShort survey

Abstract

Cells react to a variety of stresses, including accumulation of unfolded or misfolded protein, by activating the endoplasmic reticulum (EnR) stress sensor, the unfolded protein response (UPR). The UPR is highly conserved and plays a key role in the maintenance of protein folding quality control and homeostasis. In contrast to the classical reactive mode of UPR activation, recent studies describe a hormone-activated anticipatory UPR. In this pathway, mitogenic hormones, such as estrogen (E 2 ), epidermal growth factor, and vascular endothelial growth factor rapidly activate the UPR in anticipation of a future need for increased protein folding capacity upon cell proliferation. Here, we focus on this recently unveiled pathway of E 2 -estrogen receptor a (ERa) action. Notably, rapid activation of the anticipatory UPR pathway is essential for subsequent activation of the E 2 -ERa regulated transcription program. Moreover, activation of the UPR at diagnosis is a powerful prognostic marker in ERa positive breast cancer. Furthermore, in cells containing ERa mutations that confer estrogen independence and are common in metastatic breast cancer, the UPR is constitutively activated and linked to antiestrogen resistance. Lethal ERa-dependent hyperactivation of the anticipatory UPR represents a promising therapeutic approach exploited by a new class of small molecule ERa biomodulator.

Original languageEnglish (US)
Article number325
JournalFrontiers in Endocrinology
Volume9
Issue numberJUN
DOIs
StatePublished - Jun 15 2018

Fingerprint

Unfolded Protein Response
Estrogen Receptors
Cell Proliferation
Neoplasms
Protein Folding
Estrogens
Hormones
Breast Neoplasms
Endoplasmic Reticulum Stress
Estrogen Receptor Modulators
Immunologic Factors
Epidermal Growth Factor
Quality Control
Vascular Endothelial Growth Factor A
Homeostasis
Maintenance
Mutation

Keywords

  • Breast cancer
  • Calcium
  • Cancer therapy
  • Estrogen
  • Estrogen receptor a
  • Rapid extranuclear signaling
  • Unfolded protein response

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Cite this

A new role for estrogen receptor a in cell proliferation and cancer : Activating the anticipatory unfolded protein response. / Livezey, Mara; Kim, Ji Eun; Shapiro, David J.

In: Frontiers in Endocrinology, Vol. 9, No. JUN, 325, 15.06.2018.

Research output: Contribution to journalShort survey

@article{8802f90d0b15404fbff16390f2fbff9c,
title = "A new role for estrogen receptor a in cell proliferation and cancer: Activating the anticipatory unfolded protein response",
abstract = "Cells react to a variety of stresses, including accumulation of unfolded or misfolded protein, by activating the endoplasmic reticulum (EnR) stress sensor, the unfolded protein response (UPR). The UPR is highly conserved and plays a key role in the maintenance of protein folding quality control and homeostasis. In contrast to the classical reactive mode of UPR activation, recent studies describe a hormone-activated anticipatory UPR. In this pathway, mitogenic hormones, such as estrogen (E 2 ), epidermal growth factor, and vascular endothelial growth factor rapidly activate the UPR in anticipation of a future need for increased protein folding capacity upon cell proliferation. Here, we focus on this recently unveiled pathway of E 2 -estrogen receptor a (ERa) action. Notably, rapid activation of the anticipatory UPR pathway is essential for subsequent activation of the E 2 -ERa regulated transcription program. Moreover, activation of the UPR at diagnosis is a powerful prognostic marker in ERa positive breast cancer. Furthermore, in cells containing ERa mutations that confer estrogen independence and are common in metastatic breast cancer, the UPR is constitutively activated and linked to antiestrogen resistance. Lethal ERa-dependent hyperactivation of the anticipatory UPR represents a promising therapeutic approach exploited by a new class of small molecule ERa biomodulator.",
keywords = "Breast cancer, Calcium, Cancer therapy, Estrogen, Estrogen receptor a, Rapid extranuclear signaling, Unfolded protein response",
author = "Mara Livezey and Kim, {Ji Eun} and Shapiro, {David J.}",
year = "2018",
month = "6",
day = "15",
doi = "10.3389/fendo.2018.00325",
language = "English (US)",
volume = "9",
journal = "Frontiers in Endocrinology",
issn = "1664-2392",
publisher = "Frontiers Media S. A.",
number = "JUN",

}

TY - JOUR

T1 - A new role for estrogen receptor a in cell proliferation and cancer

T2 - Activating the anticipatory unfolded protein response

AU - Livezey, Mara

AU - Kim, Ji Eun

AU - Shapiro, David J.

PY - 2018/6/15

Y1 - 2018/6/15

N2 - Cells react to a variety of stresses, including accumulation of unfolded or misfolded protein, by activating the endoplasmic reticulum (EnR) stress sensor, the unfolded protein response (UPR). The UPR is highly conserved and plays a key role in the maintenance of protein folding quality control and homeostasis. In contrast to the classical reactive mode of UPR activation, recent studies describe a hormone-activated anticipatory UPR. In this pathway, mitogenic hormones, such as estrogen (E 2 ), epidermal growth factor, and vascular endothelial growth factor rapidly activate the UPR in anticipation of a future need for increased protein folding capacity upon cell proliferation. Here, we focus on this recently unveiled pathway of E 2 -estrogen receptor a (ERa) action. Notably, rapid activation of the anticipatory UPR pathway is essential for subsequent activation of the E 2 -ERa regulated transcription program. Moreover, activation of the UPR at diagnosis is a powerful prognostic marker in ERa positive breast cancer. Furthermore, in cells containing ERa mutations that confer estrogen independence and are common in metastatic breast cancer, the UPR is constitutively activated and linked to antiestrogen resistance. Lethal ERa-dependent hyperactivation of the anticipatory UPR represents a promising therapeutic approach exploited by a new class of small molecule ERa biomodulator.

AB - Cells react to a variety of stresses, including accumulation of unfolded or misfolded protein, by activating the endoplasmic reticulum (EnR) stress sensor, the unfolded protein response (UPR). The UPR is highly conserved and plays a key role in the maintenance of protein folding quality control and homeostasis. In contrast to the classical reactive mode of UPR activation, recent studies describe a hormone-activated anticipatory UPR. In this pathway, mitogenic hormones, such as estrogen (E 2 ), epidermal growth factor, and vascular endothelial growth factor rapidly activate the UPR in anticipation of a future need for increased protein folding capacity upon cell proliferation. Here, we focus on this recently unveiled pathway of E 2 -estrogen receptor a (ERa) action. Notably, rapid activation of the anticipatory UPR pathway is essential for subsequent activation of the E 2 -ERa regulated transcription program. Moreover, activation of the UPR at diagnosis is a powerful prognostic marker in ERa positive breast cancer. Furthermore, in cells containing ERa mutations that confer estrogen independence and are common in metastatic breast cancer, the UPR is constitutively activated and linked to antiestrogen resistance. Lethal ERa-dependent hyperactivation of the anticipatory UPR represents a promising therapeutic approach exploited by a new class of small molecule ERa biomodulator.

KW - Breast cancer

KW - Calcium

KW - Cancer therapy

KW - Estrogen

KW - Estrogen receptor a

KW - Rapid extranuclear signaling

KW - Unfolded protein response

UR - http://www.scopus.com/inward/record.url?scp=85048605870&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048605870&partnerID=8YFLogxK

U2 - 10.3389/fendo.2018.00325

DO - 10.3389/fendo.2018.00325

M3 - Short survey

AN - SCOPUS:85048605870

VL - 9

JO - Frontiers in Endocrinology

JF - Frontiers in Endocrinology

SN - 1664-2392

IS - JUN

M1 - 325

ER -